Weiyuan Bio Completes Tens of Millions RMB Angel Financing to Build an Open Synthetic Biology Intelligent Manufacturing Platform

Recently, Hangzhou Weiyuan Biotechnology Co., Ltd. (hereinafter referred to as “Weiyuan Biotech”) completed an angel financing round amounting to tens of millions of yuan. This round of financing received strong support from multiple industrial funds. The raised funds will be primarily used to accelerate the translation and upgrading of the company’s pilot-scale platform for chiral compounds and its efficacy evaluation system for natural products, as well as to advance the commercialization of key projects. This will facilitate the further optimization and engineering translation of the company’s technological system, injecting robust momentum into its future sustainable development.

Synthetic biology has emerged as a key area of global research and industrial focus. Particularly in sectors such as pharmaceuticals, food, materials, energy, and environmental protection, its green and sustainable characteristics demonstrate significant potential for replacing traditional chemical synthesis methods. Breakthroughs in synthetic biology not only enable the creation of organisms with novel functions but also offer distinct cost and environmental advantages over traditional chemical engineering and irrational biological fermentation technologies in the realm of biomanufacturing. Currently, countries worldwide are implementing various policies to drive the transition from traditional chemical synthesis and fermentation processes toward more environmentally friendly biomanufacturing. Synthetic biology provides enterprises with a second pathway for innovation, enhancing profit margins for existing businesses while opening up new growth opportunities through the development of new products and market expansion.

Hangzhou Weiyuan Biotechnology Co., Ltd. Since its establishment in January 2023 in Binjiang District, Hangzhou, Zhejiang Province, the company has adhered to the core values of “Seeking Truth, Intelligent Innovation, Exploring the Microscopic, and Achieving Long-term Success.” It is committed to transforming the broader world through microbial engineering and creating a better life via intelligent synthesis. As an innovative high-tech biotechnology enterprise founded by a team of senior biological engineers, enzyme engineering experts, and operational elites from the industry, Weiyuan Biotechnology brings together outstanding talents graduated from prestigious universities such as Tsinghua University, Zhejiang University, Zhejiang University of Technology, Hainan University, and Ocean University of China. The team possesses profound professional backgrounds and extensive experience in technological innovation within the fields of pharmaceuticals and bio-manufacturing engineering for high-value-added chemicals.

Weiyuan Biotechnology has established a comprehensive end-to-end layout spanning from basic scientific research and technological innovation to industrial applications, with a focus on addressing key scientific and technical challenges in the production of chiral chemicals. Leveraging intelligent enzyme evolution and high-throughput strain screening as its technological engines, and employing “Compendium of Materia Medica”-style precise analysis and intelligent prediction as its methodological tools, the company has developed a leading domestic platform for enzyme library design and construction, as well as a cell factory engineering platform. These platforms are built through the scientific planning, computational simulation, and rational design of hundreds of millions of natural and artificial enzyme elements. Driven by the dual engines of chiral compound development and functional ingredient innovation, Weiyuan Biotechnology provides raw materials and technical solutions to enterprises in the pharmaceutical, cosmetics, and food industries.

In just over a year since its establishment, Weiyuan Biotechnology has filed nine invention patents and one utility model patent, been recognized as a “Zhejiang Province Innovative Small and Medium-sized Enterprise,” and listed on the “2024 Brand List for New Infrastructure in Synthetic Biology and Bio-manufacturing.”Furthermore, the company’s innovative projects successfully advanced to the global top 100 in the “7th Zhejiang University Alumni Innovation and Entrepreneurship Competition” and won the Second Prize in the Hangzhou Division of the “China Chuangyi” Innovation and Entrepreneurship Competition, fully demonstrating the team’s strength and entrepreneurial spirit and earning widespread recognition from the industry.

“Synthetic biology, as a cutting-edge field integrating disciplines such as biology, engineering, and computer science, is opening up new pathways to address major global challenges with its revolutionary methodologies. Hangzhou Weiyuan Biotechnology Co., Ltd. has been deeply engaged in this field, committed to leveraging synthetic biology technologies to create solutions that are efficient, environmentally friendly, and sustainable. These innovations hold the promise of significantly improving human production methods and will profoundly impact our daily lives, leading a disruptive transformation.”Wu Yan, Founder and Chairman of Weiyuan BiotechnologyHe emphasized that, following the completion of this round of financing, Hangzhou Weiyuan Biotechnology Co., Ltd. will continue to deepen its research in synthetic biology technology, implement new quality productive forces, and lead the future through innovation: “We are pursuing not only short-term profit growth but also contributing to the development of the industry through continuous technological innovation and high-quality customer service. We believe that, through our efforts, we can bring more high-value-added products to the market and promote the entire industry to develop at a higher level. Let us join hands in anticipation, witness the birth of more innovative achievements on the road ahead, and jointly open a new chapter in the development of the industry!”